(Q37756105)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20481274%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Increasing use of disease modifying drugs for MS in Canada (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20481274%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

0 references

Dalia L Rotstein

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20481274%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Muhammad Mamdani

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20481274%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Paul W O'Connor

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20481274%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

1 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20481274%20AND%20SRC:MED&resulttype=core&format=json

Canadian Journal of Neurological Sciences

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20481274%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20481274%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20481274%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

383-388

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20481274%20AND%20SRC:MED&resulttype=core&format=json

Costs and quality of life of multiple sclerosis in Sweden.

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100010295

7 January 2021

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100010295

7 January 2021

Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100010295

7 January 2021

Use of ezetimibe in the United States and Canada

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100010295

7 January 2021

https://api.crossref.org/works/10.1017%2FS0317167100010295

1 reference

7 January 2021

Regional variation of multiple sclerosis prevalence in Canada

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100010295

7 January 2021

Prevalence estimates for MS in the United States and evidence of an increasing trend for women

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100010295

7 January 2021

Use of Cardiac Procedures and Outcomes in Elderly Patients with Myocardial Infarction in the United States and Canada

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100010295

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100010295

7 January 2021

Scripts for science: a new wrinkle on academic ties with industry

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100010295

7 January 2021

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100010295

7 January 2021

Contribution of incidence to increasing prevalence of multiple sclerosis in Alberta, Canada.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100010295

7 January 2021

Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100010295

7 January 2021

10.1017/S0317167100010295

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20481274%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference